Paris, May 06, 2021 – SparingVision (or the ‘Company’), a genomic medicine company developing vision saving treatments for ocular diseases, is pleased to announce that it has presented three posters highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06, at the Association for Research in Vision and Ophthalmology (‘ARVO’) 2021 Annual Meeting. Details of the posters can be found below.

Poster: SPVN06, a Novel Mutation-Independent AAV-based Gene Therapy, Protects Cone Degeneration in a Pig Model of Retinitis Pigmentosa (‘RP’) (Abstract #3543982) SparingVision administered SPVN06 via subretinal injection in pigs in their first postnatal week and evaluated its effects on cone morphology, Dr Jennifer Noel, from the University of Louisville presented the poster on May 3 2021 from 11:15 AM to 1:00 PM EDT. The administration of the AAV SPVN06 therapy was found to preserve cone morphology as well as preserve m-opsin expression in cone segments. It also leads to a greater expression of rod-derived cone viability factor (‘RdCVFL’).

Poster: Correlations between progression markers in rod-cone dystrophy due to mutations in RHO, PDE6A, or PDE6B (Abstract #3545695) Dr. Daniel Chung, Chief Medical Officer of SparingVision presented first results from the Phenorod1 retrospective natural history on May 3 2021 between 4:30 PM to 6:15 PM EDT. Strong correlations between structural and functional parameters of retinitis pigmentosa were observed and these results could help to define new composite markers for the evaluation of the disease severity; they could also be of interest when evaluating the efficacy of new therapies for treating patients with a slow progression of the disease.

Poster: A 1-Month Toxicology and Biodistribution NHP Pilot Study Evaluating a Single Subretinal Bilateral Administration of SPVN06 – A Novel AAV-Based Gene Therapy for the Treatment of Rod-Cone Dystrophies Agnostic of the Causative Mutation (Abstract #3531256)

• Dr. Melanie Marie, Principal Scientist at SparingVision presented the results from the Company’s 1-month safety study of SPVN06 in NHP on May 5, 2021 from 2:45 PM to 4:30 PM EDT. Four primates received a subretinal injection of SPVN06 and the following parameters were evaluated: clinical observations, body weights, clinical pathology, organ weights and macroscopic observations. SPVN06 was found to be well tolerated and there were no systemic effects on any of the parameters assessed.

Miriam Cortes

See Full Bio